CTLA4 and melanoma: Butyrate exhibits compartment-specific reversal: mucosal levels (10–100 mM) enhance CD8+ T cell cytotoxicity, but systemic concentrations >2.5 μM in melanoma patients correlate with CTLA-4 blockade resistance and 30% shorter PFS (152).